FDA and its collaborators should move quickly in the next year or two to start an incubator project with fact-finding activities and pilot programs to help launch a national postmarket surveillance system that builds on unique device identifiers (UDIs), registries and innovative data capture and analysis strategies, a multi-stakeholder planning board recommends.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?